You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
未名醫藥(002581.SZ)2020年淨虧1.96億元
格隆匯 04-28 23:20

格隆匯 4 月 28日丨未名醫藥(002581.SZ)披露2020年年度報吿,2020年,突如其來的新冠肺炎疫情與經濟全球化遭遇逆流相互交織,給全球帶來了巨大沖擊。疫情對人們的生命健康和經濟活動都造成了嚴重影響,使得醫藥行業於2020年首次出現了負增長。隨着醫藥行業改革的持續深入,醫保控費、重點藥物監控目錄、新版醫保目錄調整等一系列政策的密集出台,醫藥行業正在面臨更為嚴格的監管環境和激烈的市場競爭,行業利潤增速呈下降走勢,加之原料藥價格上漲、企業研發投入加大等內外部因素的多重影響,公司面臨的困難與不確定因素增多。公司報吿期實現營業收入2.77億元,同比下降51.23%;歸屬於上市公司股東的淨利潤為-1.96億元,上年同期歸屬於上市公司股東的淨利潤為6338.35萬元;基本每股收益-0.297元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account